Whalesbook
Capital Allocation Shift
Indoco Remedies has completed the sale of its ophthalmic business to Sunways (India) Private Limited for ₹110 crore. This strategic divestment exits a niche segment that accounted for only 3.2% of Indoco's standalone revenue last fiscal year. The funds from this sale will allow Indoco to focus investment on its core strengths: Active Pharmaceutical Ingredients (APIs) and complex generic formulations.
Addressing Financial Strain
The divestment is a direct response to significant financial pressures. Indoco reported a sharp increase in interest expenses to ₹45.92 crore in the fourth quarter of FY26, reaching a historic high and pushing interest coverage ratios below 1.0x. This situation has led to a consolidated net loss of ₹98.70 crore for FY26, despite overall revenue growth. Sunways, supported by private equity, sees this acquisition as a way to expand its ophthalmic offerings.
Structural Challenges Remain
While the sale provides immediate cash, Indoco's financial structure remains a concern. The company's debt-to-EBITDA ratio stands at 3.78x, indicating a need for further financial adjustments. High finance costs have heavily impacted Indoco's profitability, making it susceptible to interest rate changes. Investors are advised to exercise caution, as this divestment may only offer short-term relief and does not fully resolve the company's underlying operational cost issues.
Future Focus
The success of this strategy depends on Indoco's ability to effectively reinvest the proceeds into its USFDA-compliant facilities and API pipeline. The market is observing whether this sale marks the beginning of a sustained effort to monetize assets or is primarily a measure for immediate debt reduction. The company's future profitability hinges on its capacity to translate revenue growth into actual profits.